Pharmacoepidemiological analysis of drug therapy for asthenic syndrome as provided in Kaliningrad region

Introduction: Asthenic syndrome (AS) is increasingly prevalent, especially post-COVID, but its treatment lacks standardization due to unclear pathogenesis and diagnostic challenges. Current approaches rely on physician experience, underscoring the need for pharmacoepidemiological studies to optimize therapy. Materials and Methods: This study analyzed AS drug therapy (ICD-10 G90.8) in Kaliningrad region. A retrospective cross-sectional study of 358 patients (82 males, 276 females) evaluated outpatient and inpatient treatment using healthcare database records. Data were processed using Microsoft Access, Excel, and Statistica 13.3, with descriptive statistics (mean, median, mode, etc.). Results and Discussion: Showed 77% of AS patients were female, with monotherapy predominant (69.3% outpatients, 61.8% inpatients). Key drug subgroups included N07XX (48% outpatients, 66% inpatients – mainly succinic acid combinations) and N06BX (18% outpatients, 23% inpatients – primarily vinpocetine). Conclusion: Overall, 28 ATC drug subgroups were used, with greater variety in outpatient care. Common medications were ethylmethylhydroxyperidine succinate (EMHPS) and combinations of inosine, nicotinamide, and riboflavin. The findings highlight inconsistent prescribing patterns and the need for standardized protocols to reduce polypharmacy and improve outcomes.